Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuPath HealthTSXV:NPTH 39 Graham Number is C$0.16 as of Jun. 2026. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 373 Healthcare Providers & Services companies, NeuPath Health ranks worse than 78.55% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-08-28), the stock price of NeuPath Health is C$0.55. NeuPath Health's graham number for the quarter that ended in Jun. 2026 was C$0.16. Therefore, NeuPath Health's Price to Graham Number ratio for today is 3.48.
The historical rank and industry rank for NeuPath Health's Graham Number or its related term are showing as below:
TSXV:NPTH'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.44 Med: 14.28 Max: 24.5
Current: 3.44
During the past 7 years, the highest Price to Graham Number ratio of NeuPath Health was 24.50. The lowest was 3.44. And the median was 14.28.
TSXV:NPTH's Price-to-Graham-Number is ranked worse than 78.55% of 373
companies
in the Healthcare Providers & Services industry
Industry Median: 1.63
vs TSXV:NPTH: 3.44
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
NeuPath Health (TSXV:NPTH) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
NeuPath Health's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Jun. 2026 )
=
0.55
/
0.16
=
3.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
NeuPath Health Graham Number Related Terms
NeuPath Health Graham Number Historical Data
* Premium members only.
The historical data trend for NeuPath Health's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:NPTH vs HCA, THC, DVA: Graham Number Comparison
For the Medical Care Facilities subindustry, NeuPath Health's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuPath Health Price-to-Graham-Number vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where NeuPath Health's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuPath Health (TSXV:NPTH) has a Graham Number of C$0.16 as of Jun. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on NeuPath Health and its competitors. According to the industry distribution chart, NeuPath Health ranks #293 out of 373 companies in the Healthcare Providers & Services industry, placing it in the top 78.6%.
Is NeuPath Health's Graham Number too high?
NeuPath Health's current Graham Number is C$0.16. Based on the distribution chart, NeuPath Health ranks #293 out of 373 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's Graham Number compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, NeuPath Health ranks #293 out of 373 companies for Graham Number. This places NeuPath Health in the lower half of its industry. The industry median Graham Number is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Healthcare Providers & Services company?
The median Graham Number among Healthcare Providers & Services companies is 1.63, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on NeuPath Health and its competitors. For the Healthcare Providers & Services industry, the median Graham Number is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuPath Health's current Graham Number is C$0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current Graham Number is C$0.16. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current Graham Number is C$0.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?
Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued.
The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25.
GuruFocus considers NeuPath Health to be Significantly Overvalued.
Key valuation signals for TSXV:NPTH:
Graham Number: C$0.16
GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score
Get the complete analysis for TSXV:NPTH
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NPTH has been successfully added to your 
